Sign In
Buy EQ
$3.11
+0.320 (+11.47%)
At Close: Jun 03, 2026
Equillium to Participate in the Cantor Global Healthcare Conference 2025
04:03pm, Friday, 29'th Aug 2025
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.
Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC
05:35pm, Thursday, 28'th Aug 2025
Equillium, Inc. secured up to $50 million in funding to advance EQ504, its novel AhR modulator, for ulcerative colitis treatment. A phase 1 proof-of-concept study for EQ504 in ulcerative colitis is se
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
08:30am, Monday, 11'th Aug 2025
LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune
Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy
08:30am, Monday, 04'th Aug 2025
LA JOLLA, Calif.--(BUSINESS WIRE)-- #Bitcoin--Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced
Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504
08:00am, Thursday, 01'st May 2025
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat
Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11:01am, Tuesday, 01'st Apr 2025
After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
11:16am, Thursday, 27'th Mar 2025
Equillium, Inc. EQ released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGVHD
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
10:55am, Friday, 21'st Feb 2025
Equillium (EQ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall S
Equillium (EQ) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 10'th Feb 2025
Equillium (EQ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock
09:51am, Monday, 10'th Feb 2025
Equillium (EQ) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still tradin
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates
04:01pm, Wednesday, 13'th Nov 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat
Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth
11:05am, Wednesday, 06'th Nov 2024
Equillium (EQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Equillium, Inc. (EQ) Beats Q2 Earnings and Revenue Estimates
06:36pm, Thursday, 08'th Aug 2024
Equillium, Inc. (EQ) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to loss of $0.10 per share a year ago.
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
01:57pm, Thursday, 18'th Jul 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato
